论文部分内容阅读
目的观察分析氨氯地平阿托伐他汀钙片治疗高血压合并冠心病的临床疗效。方法选取84例高血压合并冠心病患者,将患者随机分为观察组和对照组,各42例。对照组行阿托伐他汀钙片治疗,观察组行氨氯地平阿托伐他汀钙片治疗,对比两组患者的疗程及检测指标。结果观察组治疗后收缩压(SBP)和舒张压(DBP)水平均低于对照组,差异有统计学意义(P<0.05);观察组治疗后总胆固醇(TC)、甘油三脂(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)水平变化升高较对照组明显,差异有统计学意义(P<0.05);治疗后观察组总有效率为92.86%,明显高于对照组的59.52%,两组比较差异有统计学意义(P<0.05);观察组不良反应发生率为2.38%,对照组为4.76%,差异无统计学意义(P>0.05)。结论对高血压合并冠心病患者采取氨氯地平阿托伐他汀钙片治疗的临床效果显著,且不良反应少。
Objective To observe and analyze the clinical efficacy of amlodipine atorvastatin calcium in the treatment of patients with hypertension and coronary heart disease. Methods Eighty-four patients with hypertension and coronary heart disease were enrolled. The patients were randomly divided into observation group and control group, with 42 cases in each group. The control group was treated with atorvastatin calcium, and the observation group was treated with amlodipine atorvastatin calcium tablets. The course of treatment and the detection indexes were compared between the two groups. Results The levels of SBP and DBP in the observation group after treatment were lower than those in the control group (P <0.05). After treatment, the levels of total cholesterol (TC), triglyceride (TG) , High-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) levels increased significantly compared with the control group, the difference was statistically significant (P <0.05); after treatment, the total effective rate was 92.86%, significantly higher than 59.52% of the control group, the difference between the two groups was statistically significant (P <0.05); adverse reaction rate in the observation group was 2.38%, the control group was 4.76%, the difference was not statistically significant (P> 0.05). Conclusion Amlodipine atorvastatin calcium tablets in patients with hypertension and coronary heart disease have significant clinical effects and few adverse reactions.